Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website highlighting data on mevrometostat data in prostate cancer. This news item is set to be published on February 13, on the day of the mevrometostat late breaker abstract release, notes the analyst, who says that while there is no progression free survival data in the image, the high-level news commentary “sounds very positive” for mevrometostat and Oric Pharmaceuticals (ORIC). The firm has an Overweight rating on Oric shares, which are up $1.00, or 8%, to $13.25 in morning trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Optimistic Buy Rating for Oric Pharmaceuticals Driven by Promising Data and Favorable Risk/Reward Profile
- Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Trial Data and Market Projections
- Oric Pharmaceuticals trial results ‘highly encouraging,’ says H.C. Wainwright
- Oric Pharmaceuticals to Present at J.P. Morgan Conference
- Oric Pharmaceuticals provides early Phase 1b combination data for ORIC-944